Evidence map›Paper›PMID 35953157›Full record

ReviewAdvances in pharmacology (San Diego, Calif.)2022

Assessing cytochrome P450 function using genetically engineered mouse models.

Sarrah L Hannon, Xinxin Ding

Open access · greenAbstract readReview
In one paragraph

Review in Advances in pharmacology (San Diego, Calif.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Frontiers in pharmacology · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sarrah L HannonDepartment of Pharmacology and Toxicology, Ken R. Coit College of Pharmacy, The University of Arizona, Tucson, AZ, United States.
Xinxin DingDepartment of Pharmacology and Toxicology, Ken R. Coit College of Pharmacy, The University of Arizona, Tucson, AZ, United States. Electronic address: xding@pharmacy.arizona.edu.
University of Arizona · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Bonnie LaFleur · 1985 to 2026
$110.2M
TRANSPORT OF TRACE METALS IN A POLLUTED AQUIFERP42ES004940 · NIEHS · UNIVERSITY OF ARIZONA · PI Jon D Chorover · 1990 to 2026
$68.1M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI George S Watts · 1994 to 2026
$36.7M
Training in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7M
Molecular and Cellular Basis of PCB Developmental Neurotoxicity: ViCTER supplementR01ES014901 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HANS-JOACHIM LEHMLER, Pamela J Lein · 2009 to 2026
$9.3M
Metabolic Mechanisms of Naphthalene Toxicity in LungR01ES020867 · NIEHS · WADSWORTH CENTER · PI Xinxin Ding, Laura S Van Winkle · 2013 to 2026
$6.4M
Human CYP2A and respiratory tract xenobiotic toxicityR01CA092596 · NCI · WADSWORTH CENTER · PI DING, XINXIN · 2003 to 2020
$6.1M
Translational regulation during cigarette smoking-induced reprogramming of the tRNA epitranscriptome, in vitro and in a mouse smoking modelR01ES031529 · NIEHS · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI BEGLEY, THOMAS J · 2020 to 2024
$1.9M
Characterization of Naphthalene DNA Adducts in Mice and FirefightersF31ES034268 · NIEHS · UNIVERSITY OF ARIZONA · PI HANNON, SARRAH · 2022 to 2023
$92k
NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA092596NIEHS NIH HHS F31 ES034268NIEHS NIH HHS P30 ES006694NIEHS NIH HHS P42 ES004940NIEHS NIH HHS R01 ES014901NIEHS NIH HHS R01 ES020867NIEHS NIH HHS R01 ES031529NIEHS NIH HHS T32 ES007091
6 · The paper itself

Abstract

The ability to knock out and/or humanize different genes in experimental animals, globally or in cell- and tissue-specific patterns, has revolutionized scientific research in many areas. Genetically engineered mouse models, including knockout models, transgenic models, and humanized models, have played important roles in revealing the in vivo functions of various cytochrome P450 (CYP) enzymes. These functions are very diverse, ranging from the biotransformation of drugs and other xenobiotics, events that often dictate their pharmacokinetic or toxicokinetic properties and the associated therapeutic or adverse actions, to the metabolism of endogenous compounds, such as steroid hormones and other bioactive substances, that may determine susceptibility to many diseases, such as cancer and metabolic diseases. In this review, we provide a comprehensive list of Cyp-knockout, human CYP-transgenic, and CYP-humanized mouse models that target genes in the CYP1-4 gene families, and highlight their utility in assessing the in vivo metabolism, bioactivation, and toxicity of various xenobiotic compounds, including therapeutic agents and chemical carcinogens. We aim to showcase the advantages of utilizing these mouse models for in vivo drug metabolism and toxicology studies, and to encourage and facilitate greater utility of engineered mouse models to further improve our knowledge of the in vivo functions of various P450 enzymes, which is integral to our ability to develop safer and more effective therapeutics and to identify individuals predisposed to adverse drug reactions or environmental diseases.

Indexed as

Cytochrome P-450 Enzyme SystemXenobioticsAnimalsBiotransformationHumansMiceCytochrome P-450 Enzyme SystemXenobioticsCarcinogenesisCytochrome P450Drug dispositionDrug toxicityHumanizedKnockoutMiceTransgenic

Identifiers

PMID35953157
PMCPMC10544722
OpenAlexW4285213667

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.